# Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

> **NCT03338920** · PHASE3 · TERMINATED · sponsor: **Currax Pharmaceuticals** · enrollment: 159 (actual)

## Conditions studied

- Acute Migraine With or Without Aura

## Interventions

- **DRUG:** sumatriptan nasal powder
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03338920
- **Lead sponsor:** Currax Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-02
- **Primary completion:** 2022-04-11
- **Final completion:** 2022-04-11
- **Target enrollment:** 159 (ACTUAL)
- **Why stopped:** eDiary data collected not sufficient to utilize in the analysis of protocol endpoints
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03338920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03338920, "Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03338920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*